Emerging therapies for Alzheimer’s disease: The promise of disease-modifying drugs exploring recent breakthroughs in drugs aimed at slowing or halting the progression of Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder affecting approximately 50 million individuals worldwide, with significant implications for healthcare systems and society. Recent advancements in disease-modifying therapies, targeting key pathological features such as amyloid-beta plaques, tau protein tangles, and neuroinflammation, hold promise for altering the
disease’s progression. Current treatments mainly focus on symptom relief, lacking the ability to halt neurodegeneration. Emerging therapies such as aducanumab and lecanemab aim to reduce amyloid accumulation, while novel tau-targeting strategies are under investigation. Neuroinflammatory pathways are also being explored for potential therapeutic interventions. Despite challenges in clinical efficacy and trial designs, multi-target approaches and personalized medicine may enhance treatment outcomes. Ongoing research is essential to develop effective interventions that can improve patient quality of life and reduce the societal burden of AD.